S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:VBIV

VBI Vaccines Stock Forecast, Price & News

$3.37
+0.09 (+2.74 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.25
Now: $3.37
$3.49
50-Day Range
$3.04
MA: $3.49
$4.32
52-Week Range
$0.69
Now: $3.37
$6.93
Volume6.82 million shs
Average Volume8.41 million shs
Market Capitalization$815.72 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome; and a partnership with Syneos Health, Inc. for the commercialization of VBI's 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
VBI Vaccines logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031
Employees123
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.22 million
Book Value$0.50 per share

Profitability

Net Income$-54,810,000.00
Net Margins-2,837.73%

Miscellaneous

Market Cap$815.72 million
Next Earnings Date3/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

420th out of 1,960 stocks

Pharmaceutical Preparations Industry

210th out of 771 stocks

Analyst Opinion: 3.6Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$3.37
+0.09 (+2.74 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

Is VBI Vaccines a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VBI Vaccines stock.
View analyst ratings for VBI Vaccines
or view top-rated stocks.

What stocks does MarketBeat like better than VBI Vaccines?

Wall Street analysts have given VBI Vaccines a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VBI Vaccines wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for VBI Vaccines
.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) announced its earnings results on Monday, November, 2nd. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biopharmaceutical company earned $0.30 million during the quarter, compared to the consensus estimate of $0.36 million. VBI Vaccines had a negative net margin of 2,837.73% and a negative trailing twelve-month return on equity of 36.69%.
View VBI Vaccines' earnings history
.

How has VBI Vaccines' stock price been impacted by COVID-19 (Coronavirus)?

VBI Vaccines' stock was trading at $0.9171 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VBIV shares have increased by 267.5% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VBIV?

5 analysts have issued 12 month target prices for VBI Vaccines' stock. Their forecasts range from $4.00 to $9.00. On average, they anticipate VBI Vaccines' share price to reach $6.40 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price.
View analysts' price targets for VBI Vaccines
or view top-rated stocks among Wall Street analysts.

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the following people:
  • Mr. Jeffrey R. Baxter F.C.M.A., FCMA, Pres, CEO & Director (Age 60, Pay $736.13k)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 51, Pay $452.7k)
  • Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D., Chief Medical Officer (Age 66, Pay $488.2k)
  • Mr. Christopher McNulty, CFO, Head of Bus. Devel. & Director (Age 44)
  • Nicole Anderson, Director of Corp. Communications & Investor Relations
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 56)
  • Ms. Nell Beattie, Chief Bus. Officer (Age 33)
  • Mr. Avi Mazaltov, Global Head of Manufacturing & GM of SciVac (Age 59)
  • Mr. Misha Nossov, Sr. VP of Market Access & Commercial
  • Mr. T. Adam Buckley, Sr. VP of Bus. Devel. (Age 45)

Who are some of VBI Vaccines' key competitors?

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.44%), Northern Trust Corp (0.87%), Cambridge Investment Research Advisors Inc. (0.68%), General American Investors Co. Inc. (0.68%), Charles Schwab Investment Management Inc. (0.58%) and Nuveen Asset Management LLC (0.32%). Company insiders that own VBI Vaccines stock include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc and Steven Gillis.
View institutional ownership trends for VBI Vaccines
.

Which major investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, SG Americas Securities LLC, Bailard Inc., Cambridge Investment Research Advisors Inc., Alliancebernstein L.P., Raymond James Financial Services Advisors Inc., Nuveen Asset Management LLC, and ETF Managers Group LLC.
View insider buying and selling activity for VBI Vaccines
or view top insider-selling stocks.

Which major investors are buying VBI Vaccines stock?

VBIV stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., General American Investors Co. Inc., Swiss National Bank, Creative Planning, Bank of New York Mellon Corp, First Midwest Bank Trust Division, Hsbc Holdings PLC, and Captrust Financial Advisors. Company insiders that have bought VBI Vaccines stock in the last two years include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, and Steven Gillis.
View insider buying and selling activity for VBI Vaccines
or or view top insider-buying stocks.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $3.37.

How much money does VBI Vaccines make?

VBI Vaccines has a market capitalization of $815.72 million and generates $2.22 million in revenue each year. The biopharmaceutical company earns $-54,810,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does VBI Vaccines have?

VBI Vaccines employs 123 workers across the globe.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is www.vbivaccines.com.

Where are VBI Vaccines' headquarters?

VBI Vaccines is headquartered at 222 Third Street Suite 2241, Cambridge MA, 02142.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.